The Carboxyl-Terminus of Human Immunodeficiency Virus Type 2 Circulating Recombinant form 01_AB Capsid Protein Affects Sensitivity to Human TRIM5α

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Miyamoto, Tadashi ^a   Nakayama, Emi E ^a   Yokoyama, Masaru ^b   Ibe, Shiro ^c   Takehara, Shunpei ^a   Kono, Ken ^a   Yokomaku, Yoshiyuki ^c   Pizzato, Massimo ^d   Luban, Jeremy ^d   Sugiura, Wataru ^c   Sato, Hironori ^b   Shioda, Tatsuo ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; TRIPARTITE MOTIF PROTEIN 5;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2; LEUKEMIA CELL LINE; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN DOMAIN; VIROGENESIS; VIRUS REPLICATION; VIRUS STRAIN;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CAPSID PROTEINS; CARRIER PROTEINS; CELL LINE; HIV INFECTIONS; HIV-1; HIV-2; HOST-PATHOGEN INTERACTIONS; HUMANS; JAPAN; JURKAT CELLS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTANT CHIMERIC PROTEINS; PHYLOGENY; PROTEIN STRUCTURE, TERTIARY; REASSORTANT VIRUSES; SEQUENCE ALIGNMENT;

EID: 84867662105     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047757     Document Type: Article

References (46)

1. Rowland-Jones SL, Whittle HC, (2007) Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1? Nat Immunol 8: 329-331.
2. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, et al. (1999) Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397: 436-441.
3. Huet T, Cheynier R, Meyerhans A, Roelants G, Wain-Hobson S, (1990) Genetic organization of a chimpanzee lentivirus related to HIV-1. Nature 345: 356-359.
4. Gottlieb GS, Sow PS, Hawes SE, Ndoye I, Redman M, et al. (2002) Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 185: 905-914.
5. Damond F, Worobey M, Campa P, Farfara I, Colin G, et al. (2004) Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. AIDS Res Hum Retroviruses 20: 666-672.
6. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, et al. (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848-853.
7. Sebastian S, Luban J, (2005) TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2: 40.
8. Stremlau M, Perron M, Lee M, Li Y, Song B, et al. (2006) Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proceedings of the National Academy of Sciences of the United States of America 103: 5514-5519.
9. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, et al. (2001) The tripartite motif family identifies cell compartments. Embo J 20: 2140-2151.
10. Nakayama EE, Miyoshi H, Nagai Y, Shioda T, (2005) A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection. Journal of Virology 79: 8870-8877.
11. Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD, (2004) Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proceedings of the National Academy of Sciences of the United States of America 101: 10774-10779.
12. Keckesova Z, Ylinen LM, Towers GJ, (2004) The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proceedings of the National Academy of Sciences of the United States of America 101: 10780-10785.
13. Perron MJ, Stremlau M, Song B, Ulm W, Mulligan RC, et al. (2004) TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proceedings of the National Academy of Sciences of the United States of America 101: 11827-11832.
14. Nakayama EE, Shioda T, (2010) Anti-retroviral activity of TRIM5 alpha. Rev Med Virol 20: 77-92.
15. Song H, Nakayama EE, Yokoyama M, Sato H, Levy JA, et al. (2007) A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5alphas. Journal of Virology 81: 7280-7285.
16. Price AJ, Marzetta F, Lammers M, Ylinen LM, Schaller T, et al. (2009) Active site remodeling switches HIV specificity of antiretroviral TRIMCyp. Nat Struct Mol Biol 16: 1036-1042.
17. Gamble TR, Yoo S, Vajdos FF, von Schwedler UK, Worthylake DK, et al. (1997) Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science 278: 849-853.
18. Onyango CO, Leligdowicz A, Yokoyama M, Sato H, Song H, et al. (2010) HIV-2 capsids distinguish high and low virus load patients in a West African community cohort. Vaccine 28S2: B60-B67.
19. Ibe S, Yokomaku Y, Shiino T, Tanaka R, Hattori J, et al. (2010) HIV-2 CRF01_AB: first circulating recombinant form of HIV-2. J Acquir Immune Defic Syndr 54: 241-247.
20. Marlink R, Kanki P, Thior I, Travers K, Eisen G, et al. (1994) Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265: 1587-1590.
21. Miyamoto T, Yokoyama M, Kono K, Shioda T, Sato H, et al. (2011) A single amino acid of human immunodeficiency virus type 2 capsid protein affects conformation of two external loops and viral sensitivity to TRIM5alpha. PloS one 6: e22779.
22. Kono K, Song H, Shingai Y, Shioda T, Nakayama EE, (2008) Comparison of anti-viral activity of rhesus monkey and cynomolgus monkey TRIM5alphas against human immunodeficiency virus type 2 infection. Virology 373: 447-456.
23. Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ, (2006) Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proceedings of the National Academy of Sciences of the United States of America 103: 7465-7470.
24. Anderson JL, Campbell EM, Wu X, Vandegraaff N, Engelman A, et al. (2006) Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. Journal of Virology 80: 9754-9760.
25. Pertel T, Reinhard C, Luban J, (2011) Vpx rescues HIV-1 transduction of dendritic cells from the antiviral state established by type 1 interferon. Retrovirology 8: 49.
26. Sokolskaja E, Berthoux L, Luban J, (2006) Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. Journal of Virology 80: 2855-2862.
27. Pertel T, Hausmann S, Morger D, Zuger S, Guerra J, et al. (2011) TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472: 361-365.
28. Kono K, Song H, Yokoyama M, Sato H, Shioda T, et al. (2010) Multiple sites in the N-terminal half of simian immunodeficiency virus capsid protein contribute to evasion from rhesus monkey TRIM5alpha-mediated restriction. Retrovirology 7: 72.
29. Pornillos O, Ganser-Pornillos BK, Kelly BN, Hua Y, Whitby FG, et al. (2009) X-ray structures of the hexameric building block of the HIV capsid. Cell 137: 1282-1292.
30. Ganser-Pornillos BK, Yeager M, Sundquist WI, (2008) The structural biology of HIV assembly. Curr Opin Struct Biol 18: 203-217.
31. Inagaki N, Takeuchi H, Yokoyama M, Sato H, Ryo A, et al. (2010) A structural constraint for functional interaction between N-terminal and C-terminal domains in simian immunodeficiency virus capsid proteins. Retrovirology 7: 90.
32. Bailey GD, Hyun JK, Mitra AK, Kingston RL, (2012) A structural model for the generation of continuous curvature on the surface of a retroviral capsid. J Mol Biol 417: 212-223.
33. Gao F, Yue L, White AT, Pappas PG, Barchue J, et al. (1992) Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature 358: 495-499.
34. Hillis DM, Bull JJ, (1993) An empirical test of bootstrapping as a method for assessing confidence in phylogenetic analysis. Syst Biol 42: 182-192.
35. Pear WS, Nolan GP, Scott ML, Baltimore D, (1993) Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 90: 8392-8396.
36. Lasfargues EY, Lasfargues JC, Dion AS, Greene AE, Moore DH, (1976) Experimental infection of a cat kidney cell line with the mouse mammary tumor virus. Cancer Res 36: 67-72.
37. Sheehy AM, Gaddis NC, Choi JD, Malim MH, (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
38. Dodson GG, Lane DP, Verma CS, (2008) Molecular simulations of protein dynamics: new windows on mechanisms in biology. EMBO Rep 9: 144-150.
39. Baker D, Sali A, (2001) Protein structure prediction and structural genomics. Science 294: 93-96.
40. Shirakawa K, Takaori-Kondo A, Yokoyama M, Izumi T, Matsui M, et al. (2008) Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif. Nat Struct Mol Biol 15: 1184-1191.
41. Case DA, Darden TA, Cheatham I, T.E., Simmerling CL, Wang JR, et al. (2006) AMBER 9. University of California, San Francisco.
42. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65: 712-725.
43. Ryckaert J-P, Ciccotti G, Berendsen HJC, (1977) Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. J Comput Phys 23: 327-341.
44. Ponder JW, Case DA, (2003) Force fields for protein simulations. Adv Protein Chem 66: 27-85.
45. Lee K, Chu CK, (2001) Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents. Antimicrob Agents Chemother 45: 138-144.
46. Kinomoto M, Yokoyama M, Sato H, Kojima A, Kurata T, et al. (2005) Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor. Journal of Virology 79: 5996-6004.